Pre-diagnostic plasma advanced glycation end-products and soluble receptor for advanced glycation end-products and mortality in colorectal cancer patients.
advanced glycation end‐products (AGEs)
colorectal cancer
mortality
soluble receptor of AGEs (sRAGE)
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
26 Jul 2024
26 Jul 2024
Historique:
revised:
22
04
2024
received:
12
02
2024
accepted:
10
05
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
26
7
2024
Statut:
aheadofprint
Résumé
Advanced glycation end-products (AGEs), formed endogenously or obtained exogenously from diet, may contribute to chronic inflammation, intracellular signaling alterations, and pathogenesis of several chronic diseases including colorectal cancer (CRC). However, the role of AGEs in CRC survival is less known. The associations of pre-diagnostic circulating AGEs and their soluble receptor (sRAGE) with CRC-specific and overall mortality were estimated using multivariable-adjusted Cox proportional hazards regression among 1369 CRC cases in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Concentrations of major plasma AGEs, N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : World Cancer Research Fund (WCRF)
ID : 2015/1391
Organisme : Cancer Prevention and Research Institute of Texas (CPRIT)
ID : RR200056
Informations de copyright
© 2024 UICC.
Références
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;3:209‐249.
American Cancer Society. Colorectal Cancer Facts & Figures 2020–2022. American Cancer Society; 2020.
Romaguera D, Ward H, Wark PA, et al. Pre‐diagnostic concordance with the WCRF/AICR guidelines and survival in European colorectal cancer patients: a cohort study. BMC Med. 2015;13(1):107.
Lee J, Jeon JY, Meyerhardt JA. Diet and lifestyle in survivors of colorectal cancer. Hematol Oncol Clin North Am. 2015;29(1):1‐27.
Mills KT, Bellows CF, Hoffman AE, Kelly TN, Gagliardi G. Diabetes mellitus and colorectal cancer prognosis: a meta‐analysis. Dis Colon Rectum. 2013;56(11):1304‐1319.
Yuan C, Bao Y, Sato K, et al. Influence of dietary insulin scores on survival in colorectal cancer patients. Br J Cancer. 2017;117(7):1079‐1087.
Zhu Y, Wu H, Wang PP, et al. Dietary patterns and colorectal cancer recurrence and survival: a cohort study. BMJ Open. 2013;3(2):e0022700.
Singh R, Barden A, Mori T, Beilin L. Advanced glycation end‐products: a review. Diabetologia. 2001;44(2):129‐146.
Rungratanawanich W, Qu Y, Wang X, Essa MM, Song BJ. Advanced glycation end products (AGEs) and other adducts in aging‐related diseases and alcohol‐mediated tissue injury. Exp Mol Med. 2021;53(2):168‐188.
Aragno M, Mastrocola R. Dietary sugars and endogenous formation of advanced glycation endproducts: emerging mechanisms of disease. Nutrients. 2017;9(4):385‐401.
Riehl A, Nemeth J, Angel P, Hess J. The receptor RAGE: bridging inflammation and cancer. Cell Commun Signal. 2009;7:12.
Hsieh HL, Schafer BW, Sasaki N, Heizmann CW. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun. 2003;307(2):375‐381.
Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med. 2007;7(8):777‐789.
Rojas A, Añazco C, González I, Araya P. Extracellular matrix glycation and receptor for advanced glycation end‐products activation: a missing piece in the puzzle of the association between diabetes and cancer. Carcinogenesis. 2018;39(4):515‐521.
Aglago EK, Rinaldi S, Freisling H, et al. Soluble receptor for advanced glycation end‐products (sRAGE) and colorectal cancer risk: a case–control study nested within a European Prospective Cohort. Cancer Epidemiol Biomarkers Prev. 2021;30(1):182‐192.
Chen L, Duan Z, Tinker L, et al. A prospective study of soluble receptor for advanced glycation end‐products and colorectal cancer risk in postmenopausal women. Cancer Epidemiol. 2016;42:115‐123.
Jiao L, Taylor PR, Weinstein SJ, et al. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1430‐1438.
Prasad K. Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases? Mol Cell Biochem. 2019;451(1–2):139‐144.
Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5(6B):1113‐1124.
Scheijen J, Hanssen NMJ, vanGreevenbroek MM, et al. Dietary intake of advanced glycation endproducts is associated with higher levels of advanced glycation endproducts in plasma and urine: the CODAM study. Clin Nutr. 2018;37(3):919‐925.
Aglago EK, Schalkwijk CG, Freisling H, et al. Plasma concentrations of advanced glycation end‐products and colorectal cancer risk in the EPIC study. Carcinogenesis. 2021;42:705‐713.
Wu F, Afanasyeva Y, Zeleniuch‐Jacquotte A, Zhang J, Schmidt AM, Chen Y. Temporal reliability of serum soluble and endogenous secretory receptors for advanced glycation end‐products (sRAGE and esRAGE) in healthy women. Cancer Causes Control. 2018;29(10):901‐905.
Rinaldi S, Rohrmann S, Jenab M, et al. Glycosylated hemoglobin and risk of colorectal cancer in men and women, the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomark Prev. 2008;17(11):3108‐3115.
Fedirko V, Riboli E, Tjonneland A, et al. Prediagnostic 25‐hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European populations. Cancer Epidemiol Biomarkers Prev. 2012;21(4):582‐593.
Zhang S, Li F, Younes M, Liu H, Chen C, Yao Q. Reduced selenium‐binding protein 1 in breast cancer correlates with poor survival and resistance to the anti‐proliferative effects of selenium. PLoS One. 2013;8(5):e63702.
Turovskaya O, Foell D, Sinha P, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis‐associated carcinogenesis. Carcinogenesis. 2008;29(10):2035‐2043.
Fuentes MK, Nigavekar SS, Arumugam T, et al. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum. 2007;50(8):1230‐1240.
Liang H, Zhong Y, Zhou S, Peng L. Knockdown of RAGE expression inhibits colorectal cancer cell invasion and suppresses angiogenesis in vitro and in vivo. Cancer Lett. 2011;313(1):91‐98.
Peng Y, Liu F, Qiao Y, et al. Genetically modified circulating levels of advanced glycation end‐products and their soluble receptor (AGEs‐RAGE Axis) with risk and mortality of breast cancer. Cancers (Basel). 2022;14(24):6124‐6140.
Omofuma OO, Peterson LL, Turner DP, et al. Dietary advanced glycation end‐products and mortality after breast cancer in the Women's Health Initiative. Cancer Epidemiol Biomarkers Prev. 2021;30(12):2217‐2226.
Mao Z, Aglago EK, Zhao Z, et al. Dietary intake of advanced glycation end products (AGEs) and mortality among individuals with colorectal cancer. Nutrients. 2021;13(12):4435‐4449.
Walter KR, Ford ME, Gregoski MJ, et al. Advanced glycation end products are elevated in estrogen receptor‐positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention. Breast Cancer Res Treat. 2019;173(3):559‐571.
Mukherjee TK, Reynolds PR, Hoidal JR. Differential effect of estrogen receptor alpha and beta agonists on the receptor for advanced glycation end product expression in human microvascular endothelial cells. Biochim Biophys Acta. 2005;1745(3):300‐309.
Murdocca M, Mango R, Pucci S, et al. The lectin‐like oxidized LDL receptor‐1: a new potential molecular target in colorectal cancer. Oncotarget. 2016;7(12):14765‐14780.
Butcher L, Carnicero JA, Gomez Cabrero D, et al. Increased levels of soluble receptor for advanced glycation end‐products (RAGE) are associated with a higher risk of mortality in frail older adults. Age Ageing. 2019;48(5):696‐702.
Wagner NB, Weide B, Reith M, et al. Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. Int J Cancer. 2015;137(11):2607‐2617.
Erusalimsky JD. The use of the soluble receptor for advanced glycation‐end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes. Redox Biol. 2021;42:101958.
Uribarri J, delCastillo MD, de laMaza MP, et al. Dietary advanced glycation end products and their role in health and disease. Adv Nutr. 2015;6(4):461‐473.
Chen H, Wu L, Li Y, et al. Advanced glycation end products increase carbohydrate responsive element binding protein expression and promote cancer cell proliferation. Mol Cell Endocrinol. 2014;395(1–2):69‐78.
Deng R, Wu H, Ran H, et al. Glucose‐derived AGEs promote migration and invasion of colorectal cancer by up‐regulating Sp1 expression. Biochim Biophys Acta Gen Subj. 2017;1861(5 Pt A):1065‐1074.
Muthyalaiah YS, Jonnalagadda B, John CM, Arockiasamy S. Impact of advanced glycation end products (AGEs) and its receptor (RAGE) on cancer metabolic signaling pathways and its progression. Glycoconj J. 2021;38(6):717‐734.